A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients with COVID-19 - Trial PHRR220304-004370
Access comprehensive clinical trial information for PHRR220304-004370 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Innovent Biologics (Suzhou) Co., Ltd. and is currently Terminated. The study focuses on COVID-19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR220304-004370
Phase 1/2
Terminated
Trial Details
Philippine Health Research Registry • PHRR220304-004370
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients with COVID-19
Study Focus
Interventional
Sponsor & Location
Innovent Biologics (Suzhou) Co., Ltd.
Brazil Philippines United States
Timeline & Enrollment
Phase 1/2
Mar 31, 2022
N/A
ICD-10 Classifications
COVID-19, virus identified
COVID-19, virus not identified
Coronavirus infection, unspecified site
Viral infection, unspecified
Rift Valley fever
Data Source
Philippine Health Research Registry
PHRR220304-004370
Non-Device Trial